A Systematic Review on Mucocutaneous Manifestations of Covid-19 in Children Publisher



Seirafianpour F¹ ; Mashayekhi F² ; Dodangeh M¹ ; Gharabaghloo FS² ; Koltapeh MP¹ ; Naeini AJ¹ ; Valizadeh R^{3, 4} ; Lakestani D⁵ ; Mozafarpoor S⁶ ; Goodarzi A^{7, 8} Show Affiliations
Source: Iranian Journal of Dermatology Published:2022

Abstract

Background: About 20% of patients with coronavirus disease 2019 (COVID-19) present with mucocutaneous eruptions. Early skin or dermatological manifestations can help pediatricians prevent the spread of the disease by suspecting COVID-19 in asymptomatic or minimally symptomatic patients. Methods: PubMed, Scopus, Embase, Google Scholar, and the Nottingham University website were searched on Sep. 1st, 2020, to retrieve studies regarding COVID-19-related mucocutaneous manifestations in patients under the age of 18. Results: Data were extracted from 76 articles including 38, 387 cases. Chilblain/pernio-like lesions were the most common dermatological manifestation, followed by multisystem inflammatory syndrome in children (MIS-C)/Kawasaki-like syndrome. Most dermatological signs were self-limited, presenting before, simultaneously with, or after other COVID-19 manifestations. In 40% of the affected children, these signs were the sole presentation of COVID-19. Conclusion: During the COVID-19 pandemic, each new mucocutaneous event in children, especially acral lesions with vascular color, should be considered a possible indicator of COVID-19. © 2022 Iranian Society of Dermatology.